Systematic review reveals adjuvant PD-1 inhibitor therapy improves disease-free survival in high-risk urothelial carcinoma, suggesting a beneficial treatment option.
Among patients with resected high-risk muscle-invasive urothelial carcinoma, adjuvant PD-1 inhibitor therapy significantly improves disease-free survival with an acceptable safety profile. However, due to the limited number of studies and short follow-up periods, these findings should be considered preliminary, and longer follow-up is required to confirm any potential overall survival benefit.
No takes yet. Share an insight, caveat, or question.
Kridis et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: